Steward Partners Investment Advisory, LLC Seagen Inc. Transaction History

Steward Partners Investment Advisory, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$191.51 - $216.16 $14,363 - $16,212	75 Added 24.12%	386 $81,000
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $60,982 - $67,031	-325 Reduced 51.1%	311 $59,000
Q4 2022 Feb 15, 2023	BUY	$117.37 - $139.17 $5,281 - $6,262	45 Added 7.61%	636 $81,000
Q3 2022 Nov 10, 2022	BUY	$135.27 - $180.11 $26,918 - $35,841	199 Added 50.77%	591 $81,000
Q2 2022 Aug 04, 2022	SELL	$108.81 - $179.33 $544 - $896	-5 Reduced 1.26%	392 $69,000

Q1 2022 May 02, 2022	BUY	$119.61 - $157.85 $5,502 - $7,261	46 Added 13.11%	397 $57,000
Q4 2021 Feb 08, 2022	BUY	$142.57 - $190.86 $5,560 - $7,443	39 Added 12.5%	351 $54,000
Q2 2021 Aug 13, 2021	SELL	$135.08 - $161.1 $58,489 - $69,756	-433 Reduced 58.12%	312 $49,000
Q1 2021 May 14, 2021	BUY	$137.51 - $190.8 $71,505 - $99,216	520 Added 231.11%	745 $103,000
Q4 2020 Feb 11, 2021	BUY	$164.63 - $211.93 $37,041 - $47,684	225 New	225 $39,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.